PolyNovo Limited (ASX:PNV): Wound Care Sales, Manufacturing and Regulatory Milestones

Aditi Sarkar

20 October 2026 04:53 PM AEDT

PolyNovo Limited (ASX:PNV): Wound Care Sales, Manufacturing and Regulatory Milestones

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo (ASX:PNV) reported FY26 total revenue of AUD 150.0 million, up 16.1%.
FY26 commercial sales reached AUD 138.4 million, increasing 16.7%.
FY26 EBITDA was AUD 12.1 million and net profit after tax was AUD 7.3 million.
The company targets a U.S. premarket approval submission before calendar year-end 2026.

PolyNovo Limited (ASX:PNV) develops and manufactures synthetic medical devices for treating complex wounds, using its proprietary NovoSorb biodegradable polymer technology. Its latest FY26 results detail expanding commercial sales, completed construction of a new manufacturing facility and continuing U.S. regulatory work. On 20 October 2026, PolyNovo shares were trading at AUD 0.898, down 2.45% during the session, according to the quoted market information. The company’s reported operating performance and regulatory timetable provide the principal developments for consideration.

Company Business

PolyNovo markets two complementary wound-management products: NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. BTM is a two-layer synthetic scaffold used in complex burns, trauma and surgical reconstruction; MTX is a synthetic dermal matrix without the temporary sealing membrane. Both use the company’s polymer platform, which is designed to support tissue formation before its biodegradable components are absorbed.

Headquartered in Melbourne, PolyNovo (ASX:PNV) operates internationally, including in the United States, United Kingdom, India, Hong Kong and Singapore, alongside distributor-supported markets. Commercial sales therefore depend on hospital adoption, clinician education, product registrations and the availability of suitable distribution channels. The Americas account for the largest regional contribution to reported sales.

Recent Development

In August 2026, PolyNovo released its results for the financial year ended 30 June 2026. The company reported increased commercial sales and confirmed that construction of its new manufacturing facility was complete. Validation work was progressing ahead of the intended manufacturing transition during FY27. Manufacturing output had also increased during the second half, following inventory and production changes earlier in the year.

A separate May 2026 announcement confirmed completion of the clinical study report for a U.S. pivotal trial of NovoSorb BTM in full-thickness burns, based on 12-month follow-up data. After updated U.S. Food and Drug Administration quality-system guidance took effect in February, PolyNovo (ASX:PNV) revised the sequencing of manufacturing validation within its premarket approval application. The company said it expected to submit the application before the end of calendar 2026; submission does not itself constitute regulatory approval.

Financial Performance and Sector Context

PolyNovo (ASX:PNV) recorded FY26 total revenue, including interest and other income, of AUD 150.0 million, compared with AUD 129.2 million in FY25. Commercial sales rose to AUD 138.4 million from AUD 118.6 million, representing 16.7% reported growth and 21.3% growth at constant exchange rates. This difference indicates that currency translation affected the reported sales comparison.

Regional commercial sales comprised AUD 104.1 million in the Americas, AUD 20.6 million in Europe, the Middle East and Africa, and AUD 13.7 million in Asia-Pacific. The corresponding year-on-year increases were 14.7%, 17.3% and 33.6%. These regions differ in commercial scale and market access arrangements, making geographic mix relevant when assessing aggregate performance.

FY26 EBITDA increased to AUD 12.1 million from AUD 11.2 million. Net profit after tax fell to AUD 7.3 million from AUD 13.2 million, with the company identifying non-recurring effects and a difference in tax outcomes between the periods. Its FY26 gross margin was 89.0%, compared with 95.6% in FY25, reflecting changes in finished-goods and work-in-progress inventories. The company reported AUD 23.1 million in operating cash flow and AUD 9.4 million in free cash flow.

Medical-device commercialisation is shaped by regulatory permissions, clinical evidence, surgical practice and hospital procurement. For PolyNovo (ASX:PNV), product access and reimbursement pathways remain distinct from clinical trial completion. The U.S. approval process for the proposed full-thickness-burn indication is one such regulatory consideration.

Risks to Consider

The company faces manufacturing validation and transition risks as its new facility approaches planned FY27 use. Its U.S. premarket approval application remains subject to submission review and regulatory decisions. Sales depend on clinical uptake and hospital procurement, while geographic exposure introduces currency translation effects. Changes in production scheduling and inventory balances can also affect reported gross margins and working capital.

What to Watch Next

Key scheduled items include PolyNovo’s annual general meeting on 30 October 2026, progress on manufacturing validation during FY27, and the planned U.S. application submission by calendar year-end. Future updates may clarify NovoSorb MTX distribution, regional commercial sales, cash generation and manufacturing costs. Any FDA decision would be a separate milestone after submission.

Key Insights

PolyNovo (ASX:PNV) entered FY27 following higher FY26 commercial sales and positive operating cash flow, alongside lower reported net profit and gross margin. Its disclosed priorities centre on manufacturing execution, wider use of its two NovoSorb products and completion of regulatory documentation. Subsequent financial reports and company announcements will establish how these operational priorities develop.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.